ARWR
Price
$17.21
Change
+$0.79 (+4.81%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
2.27B
112 days until earnings call
PBIGF
Price
$0.23
Change
-$0.04 (-14.81%)
Updated
Jul 21 closing price
Capitalization
81.69M
Interact to see
Advertisement

ARWR vs PBIGF

Header iconARWR vs PBIGF Comparison
Open Charts ARWR vs PBIGFBanner chart's image
Arrowhead Pharmaceuticals
Price$17.21
Change+$0.79 (+4.81%)
Volume$45.38K
Capitalization2.27B
Paradigm Biopharmaceuticals
Price$0.23
Change-$0.04 (-14.81%)
Volume$15K
Capitalization81.69M
ARWR vs PBIGF Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBIGF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. PBIGF commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and PBIGF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (ARWR: $16.42 vs. PBIGF: $0.23)
Brand notoriety: ARWR: Notable vs. PBIGF: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 172% vs. PBIGF: 174%
Market capitalization -- ARWR: $2.27B vs. PBIGF: $81.69M
ARWR [@Biotechnology] is valued at $2.27B. PBIGF’s [@Biotechnology] market capitalization is $81.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whilePBIGF’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • PBIGF’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than PBIGF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while PBIGF’s TA Score has 3 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 5 bearish.
  • PBIGF’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than PBIGF.

Price Growth

ARWR (@Biotechnology) experienced а +3.08% price change this week, while PBIGF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

ARWR is expected to report earnings on Dec 01, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($2.27B) has a higher market cap than PBIGF($81.7M). ARWR YTD gains are higher at: -12.660 vs. PBIGF (-16.539). PBIGF has higher annual earnings (EBITDA): -15.46M vs. ARWR (-68.12M).
ARWRPBIGFARWR / PBIGF
Capitalization2.27B81.7M2,778%
EBITDA-68.12M-15.46M441%
Gain YTD-12.660-16.53977%
P/E RatioN/AN/A-
Revenue545MN/A-
Total Cash1.1BN/A-
Total Debt388MN/A-
FUNDAMENTALS RATINGS
ARWR vs PBIGF: Fundamental Ratings
ARWR
PBIGF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
6263
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
8524

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBIGF's Valuation (90) in the null industry is in the same range as ARWR (94) in the Biotechnology industry. This means that PBIGF’s stock grew similarly to ARWR’s over the last 12 months.

PBIGF's Profit vs Risk Rating (100) in the null industry is in the same range as ARWR (100) in the Biotechnology industry. This means that PBIGF’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's SMR Rating (96) in the Biotechnology industry is in the same range as PBIGF (97) in the null industry. This means that ARWR’s stock grew similarly to PBIGF’s over the last 12 months.

ARWR's Price Growth Rating (62) in the Biotechnology industry is in the same range as PBIGF (63) in the null industry. This means that ARWR’s stock grew similarly to PBIGF’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for PBIGF (100) in the null industry. This means that ARWR’s stock grew significantly faster than PBIGF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRPBIGF
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
38%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
44%
Momentum
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
39%
MACD
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
43%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
37%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
45%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
N/A
Declines
ODDS (%)
Bearish Trend 13 days ago
83%
Bearish Trend 26 days ago
40%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
50%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBIGF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PPADX20.690.21
+1.03%
GMO U.S. Opportunistic Value III
CFSMX13.190.09
+0.69%
Clarkston Partners Founders
AAUTX31.070.19
+0.62%
Thrivent Large Cap Value A
JGTTX41.590.21
+0.51%
JPMorgan Growth Advantage R3
GLNMX25.03-0.02
-0.08%
MFS Global New Discovery R4

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with RGNX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+2.24%
RGNX - ARWR
53%
Loosely correlated
-0.63%
DNLI - ARWR
52%
Loosely correlated
-1.90%
IMNM - ARWR
51%
Loosely correlated
-1.82%
YMAB - ARWR
51%
Loosely correlated
-0.12%
IPSC - ARWR
51%
Loosely correlated
-4.14%
More

PBIGF and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBIGF has been loosely correlated with ABEO. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if PBIGF jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBIGF
1D Price
Change %
PBIGF100%
N/A
ABEO - PBIGF
34%
Loosely correlated
-0.16%
STTK - PBIGF
21%
Poorly correlated
-3.15%
ARWR - PBIGF
21%
Poorly correlated
+2.24%
OXBDF - PBIGF
7%
Poorly correlated
N/A
PTCHF - PBIGF
6%
Poorly correlated
N/A
More